Mode
Text Size
Log in / Sign up
N/A Completed N=192 Health Services Research

Reveal LINQ™ In-Office 2 (RIO2) Study International

Source: ClinicalTrials.gov NCT02412488 ↗
Enrolled (actual)
192
Serious AEs
1.6%
Results posted
Feb 2019
Primary outcomePrimary: Number of Participants With Untoward Events — 0 Participants

Summary

The purpose of the RIO 2 International study is to provide clinical and economic evidence to support moving the LINQ™ insertion procedure outside these traditional locations within the hospital, referred to as "out-of-cathlab".

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Untoward Events

Eligibility Criteria

Inclusion Criteria

  • Patient is indicated for continuous arrhythmia monitoring with a Reveal LINQ™ Insertable Cardiac Monitor (ICM)
  • Patient is at least 18 years of age or older if required by local regulations
  • Patient is willing to undergo ICM insertion procedure outside of the cathlab, operating room, or EP lab setting with only local anesthetic
  • Patient is willing and able to provide consent and authorize the use and disclosure of health information
  • Patient is willing and able to comply with the elements of the clinical investigation plan including the required follow-up

Exclusion Criteria

  • Patient has unusual thoracic anatomy or scarring at the insertion site which may adversely affect the success of the insertion procedure
  • Patient has reduced immune function or is otherwise at high risk for infection per physician discretion
  • Current therapy with immunosuppressive agents or chronic steroid use e.g. Prednisone greater than 20mg per day
  • Patient requires hemodialysis
  • Patient with active malignancy or history of chemotherapy or radiation treatment
  • Patient has had a recent (within 30 days) or an active infection including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia
  • Patient has had major surgery (in the past 6 months) Patient has undergone a procedure which required central venous or intra-arterial access (e.g. AF/VT ablation, EP study, coronary angiography) within the last 3 months or is scheduled for such a procedure while enrolled in the study
  • Prior history of surgical infection, prosthetic device infection, or endovascular infection, including endocarditis, in the past 12 months
  • Patient has a central venous port, an atrio-venous fistula, or a prosthetic valve
  • Patient requires conscious or moderate sedation to receive LINQ™
  • Patient already has an inserted or implanted loop recorder
  • Patient is implanted or indicated for implant with a pacemaker, ICD, CRT device
  • Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from a Medtronic study manager
  • Patient's life expectancy is less than 6 months
  • Patient is legally incapable of giving consent
  • Patient is pregnant* *Note: Possible pregnancy will be assessed by the physician asking the patient; a pregnancy test is not required
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02412488). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search